Skip to content

Sleep and Memory Consolidation in Adults With Attention Deficit Hyperactivity.

Sleep and Memory Consolidation in Adults With Attention Deficit Hyperactivity.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05876286
Acronym
HYPNOS
Enrollment
36
Registered
2023-05-25
Start date
2023-10-15
Completion date
2025-05-31
Last updated
2023-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Disorder With Hyperactivity

Keywords

Sleep, Memory

Brief summary

Attention Deficit Disorder With Hyperactivity is associated with deficits in cognition and sleep. In healthy adults, memory consolidation processes are related to sleep spindle activity in the sleep electroencephalogram. This association is poorly characterized in adults with attention deficit hyperactivity. In this study, the purpose is to characterize sleep microarchitecture disorders through the analysis of different stage of sleep EEG activity during a polysomnographic examination in adult with mixed Attention Deficit Disorder With Hyperactivity presentation compared to healthy.

Interventions

Neurological, neuropsychological, polysomnography examinations and multiple sleep latency test. The protocol is divided into three visits.

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

for all participants: * Age from 18 to 45 years old * Affiliated to the French health care system Inclusion Criteria for attention deficit hyperactivity disorder patients: * meeting Diagnostic and Statistical Manual (DSM)-5 criteria for mixed attention deficit hyperactivity disorder presentation without drug treatment for attention deficit hyperactivity disorder.

Exclusion criteria

for all participant: * People not able to give consent, neurological disease (other than neurodevelopmental disorders; or any other serious disease (cancer, addiction, systemic disease)), untreated sleep apnea, major depression (Beck inventory \> 15), untreated restless leg syndrome; pregnancy in progress or wish to become pregnant during the study or breastfeeding woman, drug treatment including benzodiazepine, neuroleptic or antidepressant before inclusion.

Design outcomes

Primary

MeasureTime frameDescription
Difference in signal power (db or μV 2) in the sigma frequency bands in N2 sleep1 daydifference between 2 groups

Contacts

Primary ContactMélanie PLANTON, PhD
planton.m@chu-toulouse.fr05 61 14 59 62

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026